UY31024A1 - VACCINE - Google Patents

VACCINE

Info

Publication number
UY31024A1
UY31024A1 UY31024A UY31024A UY31024A1 UY 31024 A1 UY31024 A1 UY 31024A1 UY 31024 A UY31024 A UY 31024A UY 31024 A UY31024 A UY 31024A UY 31024 A1 UY31024 A1 UY 31024A1
Authority
UY
Uruguay
Prior art keywords
oil
influenza
less
level below
amount
Prior art date
Application number
UY31024A
Other languages
Spanish (es)
Inventor
Emmanuel Jules Hanon
William Ripley Ballou
Original Assignee
Glaxo Smithkline Biolog A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0707697A external-priority patent/GB0707697D0/en
Priority claimed from GB0711357A external-priority patent/GB0711357D0/en
Priority claimed from GB0712062A external-priority patent/GB0712062D0/en
Priority claimed from GB0724651A external-priority patent/GB0724651D0/en
Application filed by Glaxo Smithkline Biolog A filed Critical Glaxo Smithkline Biolog A
Publication of UY31024A1 publication Critical patent/UY31024A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invencion proporciona una composicion inmunogénica contra la gripe en un volumen de dosis adecuado para su uso en seres humanos, que comprende un antígeno del virus influenza o preparacion antigénica del mismo y una composicion de adyuvante que comprende una emulsion de aceite de agua, en la que dicha emulsion de aceite en agua comprende un aceite metabolizable a un nivel inferor a 11 mg y un agente emulsivo a un nivel inferior a 5 mg y opcionalmente un tocol o un esterol a un nivel inferior a 12 mg. Adecuadamente la cantidad de antígeno de la gripe por cepa por dosis es de 15 ug de HA o una cantidad baja tal como menos de 15 ug de HA.The present invention provides an immunogenic composition against influenza in a dose volume suitable for use in humans, comprising an influenza virus antigen or antigenic preparation thereof and an adjuvant composition comprising a water oil emulsion, in which said oil-in-water emulsion comprises a metabolizable oil at a level less than 11 mg and an emulsifying agent at a level below 5 mg and optionally a tocol or a sterol at a level below 12 mg. Suitably the amount of influenza antigen per strain per dose is 15 ug of HA or a low amount such as less than 15 ug of HA.

UY31024A 2007-04-20 2008-04-15 VACCINE UY31024A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0707697A GB0707697D0 (en) 2007-04-20 2007-04-20 Vaccine
GB0711357A GB0711357D0 (en) 2007-06-12 2007-06-12 Vaccine
GB0712062A GB0712062D0 (en) 2007-06-21 2007-06-21 Vaccine
EP07070607 2007-10-10
GB0724651A GB0724651D0 (en) 2007-12-18 2007-12-18 Vaccine

Publications (1)

Publication Number Publication Date
UY31024A1 true UY31024A1 (en) 2008-11-28

Family

ID=40336327

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31024A UY31024A1 (en) 2007-04-20 2008-04-15 VACCINE

Country Status (1)

Country Link
UY (1) UY31024A1 (en)

Similar Documents

Publication Publication Date Title
AR066405A1 (en) VACCINE
CO6150191A2 (en) INFLUENZA VACCINE
CR10726A (en) VACCINE UNDERSTANDING AN OIL EMULSION WATER SUPPLIER
ES2585810T3 (en) Use of a flu virus and an oil-in-water emulsion adjuvant to induce a CD4 T cell response and / or an improved memory B cell response
BR0014281A (en) Vaccine against intranasal flu virus
BRPI0621886A8 (en) monovalent influenza vaccine composition, kit, method for producing an influenza vaccine composition for a pandemic or prepandemic situation, and uses of an influenza virus antigen or antigen preparation thereof and an adjuvant in an oil-in-water emulsion, a pandemic influenza virus antigen or antigen preparation of the influenza virus hemagglutinin antigen, a pandemic influenza virus or antigenic preparation thereof, and an oil-in-emulsion adjuvant water and an antigen or antigen preparation of a first strain of influenza
PE20151588A1 (en) VACCINE AGAINST DENGUE VIRUS
AR053360A1 (en) NEW FORMULATIONS OF VACCINES
BRPI0512757B8 (en) method of stabilizing cationic liposomes in aqueous formulations, liposome product, vaccine adjuvant, chlamydia, malaria or tuberculosis vaccine and delivery system
UA107940C2 (en) The vaccine composition that includes the saponin-containing adjuvant
RS54306B1 (en) Vaccine
CL2015002513A1 (en) Acellular vaccine against pertussis
EA201001478A1 (en) VACCINE
BR112012014689A2 (en) vaccine composition
UY31024A1 (en) VACCINE
BR112014023283A8 (en) IMMUNOGENIC COMPOSITION, SECOND IMMUNOGENIC COMPOSITION, AND METHOD FOR PREVENTION AND/OR TREATMENT AGAINST INFLUENZA DISEASE
MX2009010963A (en) Oil-in-water emulsion influenza vaccine.
DOP2009000068A (en) VACCINE UNDERSTANDING A WATER OIL EMULSION ASSISTANT
AR111910A2 (en) IMMUNOGENIC COMPOSITION THAT INCLUDES AN ADJUSTER FORMULATION, VACCINE COMPOSITION, PROCEDURE, USES, METHODS
UY29429A1 (en) IMMUNOGENIC COMPOSITION CONTAINING VIRUSES OF THE FLU OR ANCIENT PREPARATION OF THE SAME, ITS USES AND PREPARATION PROCEDURES.
SG139618A1 (en) Influenza vaccine
AR095206A1 (en) ACCELULAR VACCINE AGAINST PERTUSSIS
BRPI0609516B8 (en) use of an influenza virus or antigenic preparation thereof
UY29428A1 (en) VACCINE FORMULATIONS AGAINST THE FLU, ITS USES IN MEDICINE AND PREPARATION PROCEDURES
SG160386A1 (en) Novel composition

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20120613